BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30717602)

  • 21. Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients.
    Bradley CJ; Yabroff KR; Warren JL; Zeruto C; Chawla N; Lamont EB
    Med Care; 2016 May; 54(5):490-7. PubMed ID: 26900834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women.
    Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL
    Value Health; 2015 Dec; 18(8):1070-8. PubMed ID: 26686793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.
    Jaber Chehayeb R; Hood A; Wang X; Miksad R; Schellhorn Mougalian S; Lustberg MB; Wang SY; Greenup RA; Pusztai L; Kunst N
    JAMA Netw Open; 2022 Nov; 5(11):e2244204. PubMed ID: 36445704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
    Karve SJ; Price GL; Davis KL; Pohl GM; Smyth EN; Bowman L
    BMC Health Serv Res; 2014 Nov; 14():555. PubMed ID: 25392276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Provider treatment intensity and outcomes for patients with early-stage bladder cancer.
    Hollenbeck BK; Ye Z; Dunn RL; Montie JE; Birkmeyer JD
    J Natl Cancer Inst; 2009 Apr; 101(8):571-80. PubMed ID: 19351919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
    Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
    J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients.
    Zheng Z; Onukwugha E; Hanna N; Bikov K; Seal B; Mullins CD
    Adv Ther; 2014 Jul; 31(7):724-34. PubMed ID: 25022528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality.
    Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Qin A; Oster G
    BMC Cancer; 2011 Jun; 11():250. PubMed ID: 21676243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
    Rocque GB; Williams CP; Kenzik KM; Jackson BE; Azuero A; Halilova KI; Ingram SA; Pisu M; Forero A; Bhatia S
    Cancer; 2018 Nov; 124(21):4231-4240. PubMed ID: 30317547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
    Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
    Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer.
    Skinner KE; Haiderali A; Huang M; Schwartzberg LS
    Future Oncol; 2021 Mar; 17(8):931-941. PubMed ID: 33207944
    [No Abstract]   [Full Text] [Related]  

  • 32. Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer.
    Abraham P; Wang L; Jiang Z; Gricar J; Tan H; Kelly RJ
    Future Oncol; 2021 Jan; 17(3):291-299. PubMed ID: 32996811
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment patterns among elderly patients with stage IV breast cancer treated with HER-2-targeted therapy.
    Lang K; Hao Y; Huang H; Lin I; Rogerio JW; Menzin J
    J Comp Eff Res; 2014 Sep; 3(5):481-90. PubMed ID: 25350800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
    Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
    Pettersson K; Carlsson G; Holmberg C; Sporrong SK
    Acta Oncol; 2012 Sep; 51(7):840-8. PubMed ID: 22937953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients.
    Gilden DM; Kubisiak JM; Pohl GM; Ball DE; Gilden DE; John WJ; Wetmore S; Winfree KB
    J Med Econ; 2017 Feb; 20(2):151-161. PubMed ID: 27574722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.
    Kimura T; Takami T; Piao Y; Ntalla I; Saji S
    Breast Cancer Res Treat; 2024 Jul; 206(1):91-103. PubMed ID: 38704772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.
    Ramsey SD; Howlader N; Etzioni RD; Donato B
    J Clin Oncol; 2004 Dec; 22(24):4971-8. PubMed ID: 15611512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
    Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.